- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
BOULDER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Steve Mermelstein joined the company as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions (M&A).
“We are thrilled to welcome Steve to the SomaLogic team,” said SomaLogic Chief Executive Officer Roy Smythe, M.D. “His extensive advisory and execution expertise in the life sciences sector, focused primarily on tools and diagnostics, positions us well for successful inorganic growth. I look forward to working with Steve as we continue to rapidly scale our business.”
Steve has more than 25 years of experience providing strategic and corporate finance advice to senior management teams and boards of directors. He has executed a broad range of corporate transactions, including M&A, growth equity investments, recapitalizations, out-licensing and joint ventures.
He was previously Vice President of Strategy and Corporate Development at Agilent Technologies, where he led the M&A, Integration and Market Analysis teams. Prior to that, Steve was Managing Director at Covington Associates advising institutional-backed and middle-market companies in the life sciences sector. He also served as Managing Director at Huron Consulting Group, where he headed Huron Transaction Advisory LLC’s life sciences investment banking practice. Prior to that, he was Director at Wasserstein Perella & Co., where he was responsible for private equity and M&A advisory across various industries. Steve began his career at JPMorgan Chase & Co., where he specialized in M&A advisory and private equity investing through Chase Capital.
Steve received an AB in Government from Dartmouth College and an Executive MBA in Finance from New York University’s Stern School of Business. “I’m thrilled to be joining a tremendous team at SomaLogic, which is poised for significant continued expansion in the dynamic and fast-growing proteomics space,” he said.
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.
SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.
Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed business combination between SomaLogic and CM Life Sciences II and otherwise, including statements regarding the anticipated benefits of the business combination, the anticipated timing of the business combination, expansion plans, projected future results and market opportunities of SomaLogic. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s or CM Life Sciences II’s control. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the CM Life Sciences II’s registration
statement on Form S-4 (File No. 333-256127) (the “Registration Statement”) and the definitive proxy statement/prospectus included therein. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic and CM Life Sciences II assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither SomaLogic nor CM Life Sciences II gives any assurance that either SomaLogic or CM Life Sciences II or the combined company will achieve its expectations.
Lynn Lewis or Marissa Bych
Gilmartin Group LLC